Zimmer Biomet to acquire orthobiologics company for $155M


Zimmer Biomet signed an agreement to acquire Embody, an orthobiologics company, for $155 million.

The acquisition is expected to close in February, Zimmer Biomet said in a Jan. 5 news release. Along with the upfront cost, Zimmer Biomet could pay an additional $120 million subject to meeting regulatory and commercial milestones over three years.

Embody focuses on soft tissue healing, and its portfolio includes the Tapestry biointegrative implant for tendon healing and Tapestry RC implant for rotator cuff repair.

"Embody's differentiated products and innovative pipeline in the area of sports medicine support our continued focus on and investment in high-growth markets and underscores our commitment to bringing meaningful new advances to patients and surgeons," Bryan Hanson, president and CEO of Zimmer Biomet said in the release. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers